Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

Giuseppe Saglio, Dong-Wook Kim, Andreas Hochhaus, Simona Soverini, P. Erben, Susan Branford, Ariful Haque, Neil Gallagher, Yaping Shou, Timothy Hughes, G. Martinelli, Jerald Radich

Blood (2007) 110 (11): 1940.

https://doi.org/10.1182/blood.V110.11.1940.1940

Published: 2007

Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

C. Gambacorti-Passerini, MD, H. Kantarjian, MD, T. Bruemmendorf, MD, G. Martinelli, MD, M. Baccarani, MD, T. Fischer, MD, E.M. Pogliani, MD, B. Hewes, MD, A.D.G. Volkert, MD, N. Bardy-Bouxin, MD, J. Cortes, MD

Blood (2007) 110 (11): 473.

https://doi.org/10.1182/blood.V110.11.473.473

Published: 2007

Journal Articles

High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

G. Cimino, MD, L. Elia, PhD, Fabrizio Pane, MD, M. Vignetti, MD, P. Fazi, MD, S. Iacobelli, PhD, G. Meloni, MD, A. Vitale, MD, V. Martini, MD, G. Martinelli, MD, F. Di Raimondo, MD, M. Bonifacio, MD, F. Fabbiano, MD, G. Saglio, MD, M. Baccarani, MD, R. Foà, MD, F. Mandelli, MD

Blood (2006) 108 (11): 638.

https://doi.org/10.1182/blood.V108.11.638.638

Published: 2006

Journal Articles

A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

Blood (2006) 108 (11): 4779.

https://doi.org/10.1182/blood.V108.11.4779.4779

Published: 2006

Journal Articles

Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor.

C. Terragna, M. Renzulli, N. Testoni, T. Grafone, P. Tosi, E. Zamagni, C. Cellini, E. Ottaviani, S. Colarossi, I. Iacobucci, A. Poerio, G. Martinelli, M. Baccarani, M. Cavo

Blood (2005) 106 (11): 4363.

https://doi.org/10.1182/blood.V106.11.4363.4363

Published: 2005

Journal Articles

Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).

Blood (2005) 106 (11): 885.

https://doi.org/10.1182/blood.V106.11.885.885

Published: 2005

Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Oliver G. Ottmann, G. Martinelli, H. Dombret, H. Kantarjian, A. Hochhaus, B. Simonsson, A. Aloe, A. Apanovitch, N. Shah

Blood (2005) 106 (11): 42.

https://doi.org/10.1182/blood.V106.11.42.42

Published: 2005

Journal Articles

Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy.

Blood (2005) 106 (11): 483.

https://doi.org/10.1182/blood.V106.11.483.483

Published: 2005

Journal Articles

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.

F. Morschhauser, D. Huglo, G. Martinelli, G. Paganelli, P.L. Zinzani, D. Hadjiyiannakis, A. Liberati, T. Illidge, N. Milpied, H. Stein, J. Kalmus, P. Morel, U. Reimann, R. Marcus

Blood (2004) 104 (11): 130.

https://doi.org/10.1182/blood.V104.11.130.130

Published: 2004

Journal Articles

Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

G. Cimino, MD, L. Elia, PHD, G. Meloni, MD, L. Annino, MD, A. Chiarenza, MD, G. Martinelli, MD, F. Pane, MD, M. Montanaro, MD, P. Chiusolo, MD, A. Santoro, MD, M. Offidani, MD, M. Vignetti, MD, G. Saglio, MD, M. Baccarni, MD, F. Mandelli, MD, Robert Foa, MD

Blood (2004) 104 (11): 1082.

https://doi.org/10.1182/blood.V104.11.1082.1082

Published: 2004

Journal Articles

Interleukin-9 stimulates the proliferation of human myeloid leukemic cells

RM Lemoli, A Fortuna, A Tafuri, M Fogli, M Amabile, A Grande, MR Ricciardi, MT Petrucci, L Bonsi, G Bagnara, G Visani, G Martinelli, S Ferrari, S Tura

Blood (1996) 87 (9): 3852–3859.

https://doi.org/10.1182/blood.V87.9.3852.bloodjournal8793852

Published: 1996

Journal Articles

A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients

N Testoni, G Martinelli, P Farabegoli, A Zaccaria, M Amabile, D Raspadori, S Pelliconi, E Zuffa, C Carboni, S Tura

Blood (1996) 87 (9): 3822–3827.

https://doi.org/10.1182/blood.V87.9.3822.bloodjournal8793822

Published: 1996

Journal Articles

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells

RM Lemoli, A Fortuna, MR Motta, S Rizzi, V Giudice, A Nannetti, G Martinelli, M Cavo, M Amabile, S Mangianti, M Fogli, R Conte, S Tura

Blood (1996) 87 (4): 1625–1634.

https://doi.org/10.1182/blood.V87.4.1625.bloodjournal8741625

Published: 1996

Journal Articles

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

G Saglio, F Pane, E Gottardi, F Frigeri, MR Buonaiuto, A Guerrasio, D de Micheli, A Parziale, MN Fornaci, G Martinelli, F Salvatore

Blood (1996) 87 (3): 1075–1080.

https://doi.org/10.1182/blood.V87.3.1075.bloodjournal8731075

Published: 1996

Journal Articles

BCR breakpoint subregions and blast crisis lineage in CML patients [letter; comment]

G Martinelli, A Chiamenti, P Gasparini, PF Pignatti, A Ambrosetti, A Zaccaria, M Buzzi, N Testoni, S Tura, A Guerrasio

Blood (1992) 79 (3): 838–839.

https://doi.org/10.1182/blood.V79.3.838.838

Published: 1992

NARROW

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor.

Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.

Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy.

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.

Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

Interleukin-9 stimulates the proliferation of human myeloid leukemic cells

A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

BCR breakpoint subregions and blast crisis lineage in CML patients [letter; comment]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only